SynAct Pharma AB (STO:SYNACT)

Sweden flag Sweden · Delayed Price · Currency is SEK
17.80
+0.06 (0.34%)
Aug 29, 2025, 5:29 PM CET
0.34%
Market Cap949.28M
Revenue (ttm)n/a
Net Income (ttm)-91.07M
Shares Out53.33M
EPS (ttm)-2.01
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume117,971
Average Volume135,410
Open17.80
Previous Close17.74
Day's Range17.70 - 18.32
52-Week Range7.31 - 23.45
Beta0.99
RSI36.71
Earnings DateAug 20, 2025

About SynAct Pharma AB

SynAct Pharma AB, a clinical stage biotechnology company, researches and develops medicines for the treatment of inflammatory diseases in Sweden. The company develops AP1189, a drug candidate in Phase 2 clinical trial for the treatment of rheumatoid arthritis, idiopathic membranous nephropathy, and virus-induced respiratory insufficiency. It is also developing TXP-11, an advanced peptide agonist that is in preclinical trials for the prevention of organ failure in surgery; and various drug programs to treat auto-immune and inflammatory diseases.... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Employees 6
Stock Exchange Nasdaq Stockholm
Ticker Symbol SYNACT
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.